Remove IPO Remove Medical Remove Private Equity
article thumbnail

Behind the Buyouts: Solomon’s Leonhardt on Consumer M&A Resurgence

The Deal

But some subsectors, such as beauty, fragrance, residential services and medical spas, remained active as risk-off investors shifted deal activity toward categories they view as less discretionary, according to Leonhardt. Public markets, however, have been tepid, with the much-awaited IPO of L Catterton Management Ltd.

M&A 64
article thumbnail

Shareholders vs. Stakeholders - Understanding Corporate Responsibilities

Peak Frameworks

For example, in the 2012 Facebook IPO, common shareholders gained exposure to the tech giant's fortunes, while also securing a say in corporate matters. If you're interested in breaking into finance, check out our , Private Equity Course and , Investment Banking Course , which help thousands of candidates land top jobs every year.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Cooley’s 2023 Life Sciences M&A Year in Review: Potent Mix of Creativity and Resilience Spurs Activity Heading Into 2024

Cooley M&A

Complex and novel transaction structures for the sector also were a prominent result of the market and regulatory environment, with reverse mergers remaining a fixture and stock-for-stock deals and take-private transactions led by private equity sponsors entering the scene.

M&A 52
article thumbnail

The Full Guide to Healthcare Private Equity, from Careers to Contradictions

Mergers and Inquisitions

When you hear the words “healthcare private equity,” two thoughts probably come to mind: Wait a minute, isn’t healthcare a risky/growth-oriented sector? In most of the world, healthcare is either government-run or a mixed public/private sector. Are there many private healthcare companies for PE firms to acquire?

article thumbnail

Cooley’s 2022 Tech M&A Year in Review

Cooley M&A

However, deal activity fizzled in the second half of 2022, as high inflation, aggressive anti-inflation monetary policies, geopolitical instability, assertive antitrust regulators and tightening financing markets depressed target valuations, reduced strategic acquirer confidence and sidelined private equity sponsor buyers. trillion. [2]

M&A 52
article thumbnail

Cooley’s 2021 Life Sciences M&A Year in Review

Cooley M&A

In November, Johnson & Johnson announced that it will split itself into two publicly traded companies , separating its pharmaceutical and medical devices businesses from its consumer products business. billion strategic combination of One Medical and Iora Health – used all stock. [9] time highs in 2021.

M&A 40